Most Read Articles
5 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 4 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

No link between vitamin D and metabolic syndrome among female SLE patients

06 Nov 2019

Higher serum 25‐hydroxyvitamin D (25(OH)D) concentrations confer no protective benefit in terms of metabolic syndrome in nondiabetic women with systemic lupus erythematosus (SLE), a study suggests.

The study included 160 nondiabetic SLE women (mean age, 43.3 years), most of whom had mild disease activity (median SLEDAI‐2K score, 2; median disease duration, 11 years). The proportion of patients with an SDI ≥1 was 33.1 percent. Eighty-eight percent of the participants were taking prednisone, while 65 percent were on antimalarial therapy. Nearly half of the patients (49 percent) used concurrent immunosuppressive therapy.

Vitamin D deficiency (<20 ng/mL) was found in 40.6 percent of participants, while vitamin D insufficiency (20–29 ng/mL) was 49.4 percent. Mean serum 25(OH)D concentrations did not differ significantly in patients with neuropsychiatric (23.2 ng/mL), haematological (22.0 ng/mL) and nephritis lupus (21.7 ng/mL) manifestations.

About half of the participants (49.3 percent) had metabolic syndrome. The likelihood of having metabolic syndrome decreased with increasing quartiles of 25(OH)D concentrations (p-trend=0.03). Compared with the lowest 25(OH)D quartile, the highest quartile was associated with 60-percent reduced odds of having metabolic syndrome (odds ratio [OR], 0.4, 95 percent confidence interval, 0.2–0.9; p=0.04). Similarly, the odds of having elevated hypertriglyceridemia decreased according to increasing quartiles of 25(OH)D concentrations (p-trend=0.036).

However, this association between 25(OH)D concentrations and MetS and its individual components disappeared after controlling for body mass index and smoking.

Researchers underscored a need for large prospective studies to establish the roles of 25(OH)D in the incidence of metabolic syndrome in SLE patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 4 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.